Part I Overview Information


Department of Health and Human Services

Participating Organizations
National Institutes of Health (NIH), ( http://www.nih.gov)

Components of Participating Organizations     
National Cancer Institute (NCI), ( http://www.cancer.gov)

Title:  Biology of Breast Pre-Malignancies (R01)

Announcement Type
New

NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.

APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines included with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least 4 weeks prior to the grant submission date. See Section IV.

Request for Applications (RFA) Number: RFA-CA-07-047

Catalog of Federal Domestic Assistance Number(s)
93.393, 93.394, 93.395, 93.396, 93.399

Key Dates
Release/Posted Date: May 30, 2007
Opening Date: September 14, 2007 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): October 14, 2007
NOTE: On-time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant
institution/organization). 
Application Submission/Receipt Date(s): November 14, 2007
Peer Review Date(s): February-March, 2008
Council Review Date(s): May 2008
Earliest Anticipated Start Date(s): July 2008
Additional Information To Be Available Date (Activation Date): Not Applicable
Expiration Date: November 15, 2007

Due Dates for E.O. 12372

Not Applicable.

Additional Overview Content

Executive Summary

Exceptions from standard NIH rules:

Table of Contents


Part I Overview Information

Part II Full Text of Announcement

Section I. Funding Opportunity Description
1. Research Objectives


Section II. Award Information

1. Mechanism of Support

2. Funds Available

Section III. Eligibility Information
1. Eligible Applicants

    A. Eligible Institutions
    B. Eligible Individuals
2. Cost Sharing or Matching
3. Other-Special Eligibility Criteria

Section IV. Application and Submission Information
1. Request Application Information

2. Content and Form of Application Submission
3. Submission Dates and Times
    A. Submission, Review, and Anticipated Start Dates
          1. Letter of Intent
    B. Submitting an Application Electronically to the NIH
    C. Application Processing
4. Intergovernmental Review
5. Funding Restrictions
6. Other Submission Requirements

Section V. Application Review Information
1. Criteria
2. Review and Selection Process
    A. Additional Review Criteria
    B. Additional Review Considerations
    C. Sharing Research Data
    D. Sharing Research Resources
3. Anticipated Announcement and Award Dates

Section VI. Award Administration Information
1. Award Notices

2. Administrative and National Policy Requirements
3. Reporting

Section VII. Agency Contacts
1. Scientific/Research Contact(s)

2. Peer Review Contact(s)
3. Financial/Grants Management Contact(s)

Section VIII. Other Information - Required Federal Citations

Part II - Full Text of Announcement


Section I. Funding Opportunity Description


1. Research Objectives

Purpose

The emphasis of this Funding Opportunity Announcement (FOA) is on defining the functional, cellular, and molecular characteristics of breast pre-malignant lesions to augment and refine the classification of these lesions for determinations of risk of tumor progression. 

The NCI anticipates that this program will integrate multidisciplinary scientific approaches and generate information, reagents, methods, and other resources that will stimulate new hypotheses about human breast pre-malignancy as well as new opportunities for developing preventive and therapeutic interventions in humans.

Background

Breast cancer is the second most common cancer among women (after skin cancer) and the second leading cause of death (after lung cancer).  An estimated 178,480 women in the United States (U.S.) will have invasive breast cancer in 2007, and about 40,460 women will die from the disease this year.  Since 1977, added support for breast cancer research has come from funding through the highly successful Stamp-Out Act, under which the U.S. Postal Service created and sells a special-issue postage stamp with a surcharge above the first-class postage rate to support breast cancer research.  The surplus proceeds from these funds go to support breast cancer research through grants awarded by the National Cancer Institute and the Department of Defense Breast Cancer Research Program.

The NCI decided to use the currently available funds to institute a trans-NCI program in breast pre-malignancy that would encompass research areas of all the NCI divisions, including prevention, etiology, biology, diagnosis, and molecular epidemiology.  The intent of this FOA, which is part of the Trans-NCI Program on Breast Pre-malignancies, is to stimulate multidisciplinary characterizations of the genetic, molecular, cellular, and/or functional biology of pre-malignant states that may give rise to human breast cancer.

The information developed in this program will serve as a resource for the cancer research community.  The resulting compendium of cellular, genetic, metabolic, genomic, molecular, and functional differences will be useful to distinguish among clinically important types of human breast pre-malignancies.  Defining the characteristics of pre-malignancies that are substantial indicators of increased risk of developing invasive cancer should result in significant clinical benefit by inspiring the development of new means to inhibit, delay, and/or reverse these lesions in patients.

The NCI as well as experts in the extramural scientific community recommend further research related to the biology of the pre-malignant state in human breast cancer.  An expert panel convened at the November 2004 NCI Workshop on Pre-Cancers identified delineation of the biological, genetic, and functional characteristics of pre-cancers as major scientific needs (Cancer Detect Prev. 2006;30(5):387-94).  The distinctive early lesions that occur have characteristic properties that should permit them to be detected, diagnosed, and prevented from progressing to invasive cancer.  The Workshop participants noted a number of impediments to conducting research on pre-cancers, including:

The American Association for Cancer Research (AACR) Task Force on Intraepithelial Neoplasia has recommended a research focus on pre-cancerous lesions as targets for new agent development, because of the close association between dysplasia and invasive cancer (Clin Cancer Res. 2002 Feb;8(2):314-46).  Additionally, the NCI Breast Cancer Progress Report, which documented trends in the NCI breast cancer research portfolio from 1998 – 2003, stated that the overarching basic biological questions tha need to be answered involve the understanding of the normal and early malignant biology of the mammary gland, and identifying factors responsible for metastatic disease (http://planning.cancer.gov/disease/breast.shtml).

Breast Pre-malignancy – An Opportunity: There is currently little understanding of the factors that determine whether or not a pre-malignant lesion will progress to cancer.

Breast cancer is a disease of mammary tissue in which the epithelial cells and those of the stroma (including fibroblasts, immune cells, adipocytes, smooth muscle cells, and vascular cells) collaborate to generate malignancy.  Many invasive breast cancers evolve over long periods from specific pre-existing benign lesions, providing an ample window of opportunity for early detection and intervention.  However, the success of future interventional approaches requires a biological knowledge base that is, at the present time, sparse.

The NCI supports a variety of networks, consortia, and technology development programs designed for the following goals: to develop and apply highly sensitive enabling analytical technologies (the Innovative Molecular Analysis Technologies Program); to acquire and share specimen resources (the NCI Specimen Resource Locator and the Cancer Diagnosis Program and its tissue resources; to deploy risk and outcome data (NCI Research Resources epidemiological resources and statistics) as well as resources from family registries and research consortia (the Epidemiology and Genetics Research  Program) and from Genome-wide Association Studies; and to develop and use experimental and computational models and approaches (the Mouse Models of Human Cancers Consortium, the Integrative Cancer Biology Program, and the Tumor Microenvironment Network), imaging, proteomics, and nanotechnologies for exploring cancer biology and developing progression and risk models.  An example of another very valuable tissue resource is one initiated and maintained by the Friends for Life project.  This collaborative program was created to meet the need articulated by scientists conducting breast cancer research, namely that the understanding of abnormalities leading to breast cancer is hindered by inadequate knowledge about what is “normal”. The Friends for Life partnership of patient advocates and clinicians is developing a bank of normal breast tissues from healthy volunteers.

Through this FOA, the NCI strongly encourages diverse communities of cancer researchers supported through programs such as the ones cited above and similar appropriate programs to collaborate to address long-standing questions about the evolution of different pre-malignant lesions from normal breast tissue, to define their distinguishing characteristics, and to delineate and model the relationships of those characteristics to neoplastic progression.

The Research Challenge:  The NCI recognizes that defining the functional attributes of pre-malignant stages of human breast cancer, including the relevant properties of individual tissues tissue components of pre-malignant stages of human breast cancer is scientifically and technologically challenging.  Filling these knowledge gaps would have major impacts on the detection and prevention of invasive malignancies.  However, early lesions are heterogenous.  Moreover, specimens of some kinds of histologically defined breast pre-malignancies are scarce.  These factors complicate comparisons among early lesions that would lead to understanding of the biology of breast pre-malignancies.  The difficulty of investigating breast pre-cancers may underlie the low number of NCI grants devoted to this topic, in contrast to the markedly more extensive ongoing research effort oriented on the malignant stages of breast cancer.

Of the many types of benign lesions found in the human breast, several have clinically significant pre-malignant potential.  Not all early lesions progress to invasive cancer, and many regress at a high rate.  Differentiating by morphology or with non-invasive imaging those lesions likely to regress or not progress from those likely to progress to invasive disease is not possible at the present time.  As a result of current lack of methods for discrimination, many patients with pre-malignancies are subjected to expensive, invasive procedures and intensive surveillance programs.  For some patients, this degree of surveillance is probably unnecessary, but physicians cannot readily identify those patients most likely to benefit from enhanced surveillance.  Furthermore, for morphologically unapparent pre-malignancies, the inability to recognize the lesion as a precursor to cancer results in a missed opportunity to study the early lesions on a molecular basis.

Breast pre-malignancies in specific categories are histologically similar; however, it is possible that their underlying functional, molecular, and genetic properties may distinguish the stable or regressing ones from those that will advance.  Recent gene expression analyses of established breast malignancies document that breast cancers evolve by highly diverse mechanisms.  However, most research studies of pre-malignancies, normal breast tissue, and frank malignancies have focused on the genetic and molecular properties of only the epithelial cells.  There is a critical need to examine all of the cell types that comprise early lesions for their genetic, epigenetic, genomic, and other properties.  Comparisons of these properties may allow for identifications of biomarkers that can be used to distinguish the various types of pre-malignant cells and tissues from each other as well as from cells and tissues that are normal or cancerous.    The comparison may pinpoint cells with stem cell characteristics in all, or only some, early lesions.  The observed molecular, genetic, and epigenetic characteristics and evidence of structural or functional changes may be exploited to develop new diagnostic criteria, biomarkers for molecular epidemiology studies, and/or probes for non-invasive imaging.

Benefits of a Multidisciplinary Approach:  Many approaches are required to discover the biological differences among the pre-malignant subtypes.  For example, using appropriate specimens with pre-malignant lesions, investigators may employ highly sophisticated in vitro culture and in vivo transplant model systems to catalog the functional and molecular properties of early lesions.  Coupled with knowledge of the underlying risk and outcome data that accompanies these specimens, studies may define the propensity of lesions to progress and lead to development of new risk models.  Putative stem cells for the various tissue components may have properties that could allow investigators to distinguish among pre-cursor lesions.  Many of the pre-malignant specimens previously collected and stored have associated gene expression and genomic profiling data, extensive histologic data, and other analyses.  These data may help refine the search for subtle differences.  For example, micro-dissection to isolate individual cells from culture model systems may be followed by proteomic and metabolomic analyses by newly developed and highly sensitive techniques.  Proteomics provides insights into changes in enzyme expression and metabolomics represents a read-out of the actual products of activated enzymatic pathways.  These two complementary approaches are not yet fully exploited in pre-malignancy research.  The quantity of material in a pre-malignant specimen is usually limited; thus, ultra-sensitive chemistry and spectroscopy techniques are required for discovery.  Sophisticated imaging and nanotechnology techniques used in vitro and in vivo hold exceptional translational promise; the strategies for imaging organotypic cultures or transplants of early lesions are important intermediates for eventual development of diagnostic imaging.

Equally important is the opportunity for diverse research communities to cooperate within this program to decide which aspects of breast pre-malignancy biology research are most likely to have the most substantial translational impacts in the near term.  One requirement of this RFA will be for the applicants to demonstrate integration of appropriate scientific and clinical viewpoints in determining the objectives of the research.

Objectives and Scope

The emphasis of this FOA is on defining the functional, cellular, and molecular characteristics of breast pre-malignant lesions.  Where possible, applicants should take advantage of existing and well-annotated collections of breast pre-malignant specimens, the population cohorts from which they were derived, and the related clinical, epidemiologic, and population data.  Applicants may apply to these resources new and established imaging approaches for cell or tissue preparations, biochemical, proteomic, genomic, and genetic approaches, and quantitative modeling to discover what may be very subtle variations in the genomes, metabolism, and functions of pre-malignant lesions.  Applicant groups are encouraged to exploit the following resources: well-annotated human specimen collections; clinical and epidemiological data that pertain to those collections; leads generated from information from appropriate animal models; technologies to isolate discrete cell types; new cell culture and transplantation methods; imaging and nanotechnology approaches; and highly sensitive biochemical and molecular analyses in their research plans.

Areas of investigation may include, but are not limited to:

The discoveries resulting from proposed projects should enable further basic and translational research and inform clinical practice with regard to breast pre-malignancies and breast cancers.  For example, these benefits are expected to include: new avenues for pre-malignant biology research; information to inform future directions for cross-species comparisons; identification of the pre-malignant states that are most likely to progress to invasive, metastatic cancers; detection of pre-malignancy properties that predict unacceptable toxicities from available interventions; defining new interventional targets for pre-malignant lesions; and enabling focused epidemiological studies to identify additional risk factors that contribute to pre-malignancy.

The NCI expects that awardees will make publicly available all data (i.e., information), resources, reagents, and technologies that they develop under projects funded through this RFA.  The plans for data sharing must include a statement that data will be deposited in an appropriate database compatible with those developed and maintained by the NCI Center for Bioinformatics, if a suitable database exists, or a readily accessible alternative.  Grantees will be expected to make data public within 6 months of publication of results or within 1 year of data generation, whichever comes first. 

Section II. Award Information


1. Mechanism of Support

This Funding Opportunity Announcement (FOA) will use the NIH Research Project Grant (R01) award mechanism.   

The applicant will be solely responsible for planning, directing, and executing the proposed project.

This FOA uses “Just-in-Time” information concepts.  It also uses the modular as well as the non-modular budget formats (see http://grants.nih.gov/grants/funding/modular/modular.htm).  Specifically, if you are a U.S. organization and are submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs), use the PHS398 Modular Budget component provided in the SF424 (R&R) Application Package and SF424 (R&R) Application Guide (see specifically Section 5.4, “Modular Budget Component,” of the Application Guide).

U.S. applicants requesting more than $250,000 in annual direct costs must complete and submit budget requests using the Research & Related Budget component found in the application package for this FOA.

This FOA is a one time solicitation.

2. Funds Available

NCI intends to commit up to $4.5 million over Fiscal Years 2008, 2009, and 2010 to fund two to three new grants in response to the FOA.

An applicant may request a project period up to 3 years and a budget of not more than $650,000 in total costs.

Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.  Although the financial plans of the NCI provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

NIH grants policies as described in the NOT-OD-05-004, November 2, 2004.

Section III. Eligibility Information

1. Eligible Applicants

1.A.  Eligible Institutions

You may submit an application(s) if your institution/organization has any of the following characteristics:

Non-Domestic (non-U.S.) entities are not eligible to apply but may be included as participants under consortium with Domestic applicant institutions.

1.B. Eligible Individuals

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with his/her organization to develop an application for support.  Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

NIH intramural investigators may be included as collaborators under consortiums/multidisciplinary teams with eligible applicant institutions.  However, the applicant may NOT request funds for salary and research costs for the NIH intramural component.

More than one PD/PI, or multiple PDs/PIs, may be designated on the application for projects that require a “team science” approach that clearly does not fit the single-PD/PI model.  Additional information on the implementation plans and policies and procedures to formally allow more than one PD/PI on individual research projects is available at http://grants.nih.gov/grants/multi_pi.  All PDs/PIs must be registered in the NIH eRA Commons prior to the submission of the application (see http://era.nih.gov/ElectronicReceipt/preparing.htm for instructions).

The decision of whether to apply for a single PD/PI or multiple PD/PI grant is the responsibility of the investigators and applicant organizations and should be determined by the scientific goals of the project.  Applications for multiple PD/PI grants will require additional information, as outlined in the instructions below.  The NIH review criteria for approach, investigators, and environment have been modified to accommodate applications involving either a single PD/PI or multiple PDs/PIs.  When considering multiple PDs/PIs, please be aware that the structure and governance of the PD/PI leadership team as well as the knowledge, skills, and experience of the individual PD/PIs will be factored into the assessment of the overall scientific merit of the application.  Multiple PDs/PIs on a project share the authority and responsibility for leading and directing the project, intellectually and logistically.  Each PD/PI is responsible and accountable to the grantee organization, or, as appropriate, to a collaborating organization, for the proper conduct of the project or program, including the submission of required reports.  For further information on multiple PDs/PIs, please see http://grants.nih.gov/grants/multi_pi.

2. Cost Sharing or Matching

This program does not require cost sharing as defined in the current NIH Grants Policy Statement.

3. Other-Special Eligibility Criteria

Applicants may submit more than one application, provided each application is scientifically distinct.

Section IV. Application and Submission Information


To download a SF424 (R&R) Application Package and SF424 (R&R) Application Guide for completing the SF424 (R&R) forms for this FOA, link to http://www.grants.gov/applicants/apply_for_grants.jsp and follow the directions provided on that Web site.

A one-time registration is required for institutions/organizations at both:

PDs/PIs should work with their institutions/organizations to make sure they are registered in the eRA Commons.

Several additional separate actions are required before an applicant institution/organization can submit an electronic application, as follows:

1) Organizational/Institutional Registration in Grants.gov/Get Registered

2) Organizational/Institutional Registration in the eRA Commons

3) Project Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.

Both the PD/PI(s) and AOR/SO need separate accounts in the NIH eRA Commons since both are authorized to view the application image.

Note that if a PD/PI is also an NIH peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only.  These are different than any DUNS number and CCR registration used by an applicant organization.  Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government.

Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.gov and the Commons.  The NIH will accept electronic applications only from organizations that have completed all necessary registrations.

1. Request Application Information

Applicants must download the SF424 (R&R) application forms and the SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.

Note: Only the forms package directly attached to a specific FOA can be used. You will not be able to use any other SF424 (R&R) forms (e.g., sample forms, forms from another FOA), although some of the "Attachment" files may be useable for more than one FOA.

For further assistance, contact GrantsInfo -- Telephone: 301-435-0714; Email: GrantsInfo@nih.gov.

Telecommunications for the hearing impaired: TTY 301-451-5936.

2. Content and Form of Application Submission

Prepare all applications using the SF424 (R&R) application forms and in accordance with the SF424 (R&R) Application Guide for this FOA through Grants.gov/Apply.

The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to NIH.  There are fields within the SF424 (R&R) application components that, although not marked as mandatory, are required by NIH (e.g., the “Credential” log-in field of the “Research & Related Senior/Key Person Profile” component must contain the PD/PI’s assigned eRA Commons User ID).  Agency-specific instructions for such fields are clearly identified in the Application Guide.  For additional information, see “Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.”

The SF424 (R&R) application has several components.  Some components are required, others are optional.  The forms package associated with this FOA in Grants.gov/APPLY includes all applicable components, required and optional.  A completed application in response to this FOA includes the data in the following components:

Required Components:
SF424 (R&R) (Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project Information
Research & Related Senior/Key Person
PHS398 Cover Page Supplement
PHS398 Research Plan
PHS398 Checklist
PHS398 Modular Budget or Research & Related Budget, as appropriate (See Section IV.6., “Special Instructions,” regarding appropriate required budget component.)   

Optional Components:
PHS398 Cover Letter File
Research & Related Subaward Budget Attachment(s) Form

SPECIAL INSTRUCTIONS  

Applications with Multiple PDs/PIs

When multiple PDs/PIs are proposed, NIH requires one PD/PI to be designated as the "Contact” PI, who will be responsible for all communication between the PDs/PIs and the NIH, for assembling the application materials outlined below, and for coordinating progress reports for the project.  The contact PD/PI must meet all eligibility requirements for PD/PI status in the same way as other PDs/PIs, but has no other special roles or responsibilities within the project team beyond those mentioned above.

Information for the Contact PD/PI should be entered in Item 15 of the SF424(R&R) Cover component.  All other PDs/PIs should be listed in the Research & Related Senior/Key Person component and assigned the project role of “PD/PI.”  Please remember that all PDs/PIs must be registered in the eRA Commons prior to application submission.  The Commons ID of each PD/PI must be included in the “Credential” field of the Research & Related Senior/Key Person component.  Failure to include this data field will cause the application to be rejected.

All projects proposing Multiple PDs/PIs will be required to include a new section describing the leadership of the project.

Multiple PD/PI Leadership Plan: For applications designating multiple PDs/PIs, a new section of the research plan, entitled “Multiple PD/PI Leadership Plan” (Section 14 of the Research Plan Component in the SF424 (R&R)), must be included.  A rationale for choosing a multiple PD/PI approach should be described.  The governance and organizational structure of the leadership team and the research project should be described, including communication plans, process for making decisions on scientific direction, and procedures for resolving conflicts.  The roles and administrative, technical, and scientific responsibilities for the project or program should be delineated for the PDs/PIs and other collaborators.

If budget allocation is planned, the distribution of resources to specific components of the project or the individual PDs/PIs should be delineated in the Leadership Plan.  In the event of an award, the requested allocations may be reflected in a footnote on the Notice of Award.

Applications Involving a Single Institution

When all PDs/PIs are within a single institution, follow the instructions contained in the SF424 (R&R) Application Guide.

Applications Involving Multiple Institutions 

When multiple institutions are involved, one institution must be designated as the prime institution and funding for the other institution(s) must be requested via a subcontract to be administered by the prime institution.  When submitting a detailed budget, the prime institution should submit its budget using the Research & Related Budget component.  All other institutions should have their individual budgets attached separately to the Research & Related Subaward Budget Attachment(s) Form.  See Section 4.8 of the SF424 (R&R) Application Guide for further instruction regarding the use of the subaward budget form.

When submitting a modular budget, the prime institution completes the PHS398 Modular Budget component only. Information concerning the consortium/subcontract budget is provided in the budget justification.  Separate budgets for each consortium/subcontract grantee are not required when using the Modular budget format.  See Section 5.4 of the Application Guide for further instruction regarding the use of the PHS398 Modular Budget component.

3. Submission Dates and Times

See Section IV.3.A.for details.

3.A. Submission, Review, and Anticipated Start Dates
Opening Date: September 14, 2007 (Earliest date an application may be submitted to Grants.gov).
Letters of Intent Receipt Date(s): October 14, 2007
Application Submission/Receipt Date(s): November 14, 2007 
Peer Review Date(s): February-March, 2008
Council Review Date(s): May 2008
Earliest Anticipated Start Date(s): July 2008

3.A.1. Letter of Intent

Prospective applicants are asked to submit a letter of intent that includes the following information:

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows the NCI staff to estimate the potential review workload and plan the review.

The letter of intent is to be sent by the date listed in Section IV.3.A.

The letter of intent should be sent to:

Anne S. Tatem
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, Suite 5056, MSC 7380
Bethesda, MD 20892-7380
Telephone: (301) 594-5371
Fax: (301) 496-8656
Email: tatema@mail.nih.gov

3.B. Submitting an Application Electronically to the NIH

To submit an application in response to this FOA, applicants should access this FOA via http://www.grants.gov/applicants/apply_for_grants.jsp  and follow Steps 1-4. Note:  Applications must only be submitted electronically.  PAPER APPLICATIONS WILL NOT BE ACCEPTED

3.C. Application Processing

Applications may be submitted on or after the opening date and must be successfully received by Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization) on the application submission/receipt date(s).  (See Section IV.3.A. for all dates.)  If an application is not submitted by the receipt date(s) and time, the application may be delayed in the review process or not reviewed.

Once an application package has been successfully submitted through Grants.gov, any errors have been addressed, and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have 2 business days to view the application image.

Upon receipt, applications will be evaluated for completeness by the CSR and responsiveness by the NCI. Incomplete and non-responsive applications will not be reviewed.  If the application is not responsive to the RFA, NIH staff may contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next appropriate NIH review cycle.

There will be an acknowledgement of receipt of applications from Grants.gov and the Commons.  The submitting AOR receives the Grants.gov acknowledgments.  The AOR and the PI receive Commons acknowledgments.  Information related to the assignment of an application to a Scientific Review Group is also in the Commons. 

Note: Since email can be unreliable, it is the responsibility of the applicant to check periodically on their application status in the Commons.

The NIH will not accept any application in response to this funding opportunity that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application.  However, when a previously unfunded application, originally submitted as an investigator-initiated application, is to be submitted in response to a funding opportunity, it is to be prepared as a NEW application.  That is, the application for the funding opportunity must not include an “Introduction” describing the changes and improvements made, and the text must not be marked to indicate the changes from the previous unfunded version of the application.

4. Intergovernmental Review

This initiative is not subject to intergovernmental review.

5. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable.  A grantee may, at its own risk and without NIH prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new or competing renewal (formerly “competing continuation”) award if such costs: are necessary to conduct the project, and would be allowable under the grant, if awarded, without NIH prior approval.  If specific expenditures would otherwise require prior approval, the grantee must obtain NIH approval before incurring the cost.  NIH prior approval is required for any costs to be incurred more than 90 days before the beginning date of the initial budget period of a new or competing renewal award.

The incurrence of pre-award costs in anticipation of a competing or non-competing award imposes no obligation on NIH either to make the award or to increase the amount of the approved budget if an award is made for less than the amount anticipated and is inadequate to cover the pre-award costs incurred.  NIH expects the grantee to be fully aware that pre-award costs result in borrowing against future support and that such borrowing must not impair the grantee's ability to accomplish the project objectives in the approved time frame or in any way adversely affect the conduct of the project.  See the NIH Grants Policy Statement.

6. Other Submission Requirements

PD/PI Credential (e.g., Agency Login)

The NIH requires the PD/PI(s) to fill in his/her Commons User ID in the “PROFILE – Project Director/Principal Investigator” section, “Credential” log-in field of the “Research & Related Senior/Key Person Profile” component.

Organizational DUNS

The applicant organization must include its DUNS number in its Organization Profile in the eRA Commons.  This DUNS number must match the DUNS number provided at CCR registration with Grants.gov.  For additional information, see “Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.”

PHS398 Research Plan Component Sections

Items 2-5 of the PHS398 Research Plan component are limited to 25 pages.  While each section of the Research Plan component needs to be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan component as a single document, separating sections into distinct PDF attachments just before uploading the files.  This approach will enable applicants to better monitor formatting requirements such as page limits.  All attachments must be provided to NIH in PDF format, filenames must be included with no spaces or special characters, and a .pdf extension must be used.   

All application instructions outlined in the SF424 (R&R) Application Guide are to be followed, incorporating "Just-in-Time" information concepts, and with the following additional requirements:

Special Instructions for Modular Grant Applications

R01 applications from U.S. institutions/organizations requesting up to $250,000 per year in direct costs (excluding consortium F&A costs) must be submitted in a modular budget format.  Additional information on modular budgets is available at http://grants.nih.gov/grants/funding/modular/modular.htm.  When submitting a modular budget, the applicant organization will include only the PHS398 Modular Budget component.  See Section 5.4 of the SF424 (R&R) Application Guide for further instructions regarding the use of the PHS398 Modular Budget component.

Appendix Materials

NIH has published new limitations on grant application appendix materials to encourage applications to be as concise as possible while containing the information needed for expert scientific review. (See http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-018.html).

Applicants must follow the specific instructions on Appendix materials as described in the SF424 (R&R) Application Guide (see http://grants.nih.gov/grants/funding/424/index.htm).

Do not use the Appendix to circumvent the page limitations of the Research Plan component.  An application that does not observe the required page limitations may be delayed in the review process.

Note: While each section of the PHS398 Research Plan component needs to be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan component as a single document, separating sections into distinct PDF attachments just before uploading the files.  This approach will enable applicants to monitor better formatting requirements such as page limits.  All attachments must be provided to NIH in PDF format, filenames must be included with no spaces or special characters, and a .pdf extension must be used.

Plan for Sharing Research Data

Awardees are expected to make all data provided under this FOA publicly available.   Where possible, grantees will deposit data into a database developed and maintained by the NCI Center for Bioinformatics (NCI CB).  Grantees will be expected to make data public within six months of publication of research results or within a year of data generation, whichever comes first.

The precise content of the data-sharing plan will vary, depending on the data collected and how the investigator is planning to share the data.  Applicants must describe briefly:  The expected schedule for data sharing; the format of the final dataset; the documentation to be provided, whether or not any analytic tools also will be provided; whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not any conditions will be placed on their use); and, the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal Website, through a data archive or enclave.)  Investigators choosing to share under their own auspices may wish to enter into a data-sharing agreement.  References to data sharing may also be appropriate in other sections of the application.

All applicants must include a plan for sharing research data in their application or explain why sharing is not possible.  The data sharing policy is available at http://grants.nih.gov/grants/policy/data_sharing.  All investigators responding to this FOA should include a description of how final research data will be shared.

The reasonableness of the data sharing plan or the rational for not sharing research data will be assessed by the reviewers.  However, reviewers will not factor the proposed data sharing plan into the determination of the scientific merit or the priority score.  The presence of a data sharing plan will be part of the terms and conditions of the award.

Sharing Research Resources

NIH policy expects that grant recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (see the NIH Grants Policy Statement at http://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#_Toc54600131). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.

The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications.  The effectiveness of the resource sharing will be evaluated as part of the administrative review of each Non-Competing Grant Progress Report (PHS 2590).  See Section VI.3., “Reporting.”

Section V. Application Review Information


1. Criteria 

Only the review criteria described below will be considered in the review process.

2. Review and Selection Process

Applications submitted for this funding opportunity will be assigned to the NIH Institutes and Centers (ICs) on the basis of established U.S. Public Health Service (PHS) referral guidelines.

Applications that are complete and responsive to the FOA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NCI in accordance with the review criteria stated below.

As part of the initial merit review, all applications will:

Applications submitted in response to this funding opportunity will compete for available funds with all other recommended applications.  The following will be considered in making funding decisions:

The goals of NIH supported research are to advance our understanding of biological systems, to improve the control of disease, and to enhance health.  In their written critiques, reviewers will be asked to comment on each of the following criteria in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals.  Each of these criteria will be addressed and considered in assigning the overall score, weighting them as appropriate for each application.

Note that an application does not need to be strong in all categories to be judged likely to have major scientific impact and thus deserve a high priority score.  For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward.

Significance: Does this study address an important problem?  If the aims of the application are achieved, how will scientific knowledge or clinical practice be advanced?  What will be the effect of these studies on the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Specific to this RFA:


Approach: Are the conceptual or clinical framework, design, methods, and analyses adequately developed, well integrated, well reasoned, and appropriate to the aims of the project?  Does the applicant acknowledge potential problem areas and consider alternative tactics?  For applications designating multiple PDs/PIs, is the leadership approach, including the designated roles and responsibilities, governance, and organizational structure, consistent with and justified by the aims of the project and the expertise of each of the PDs/PIs?

Specific to this RFA:

Innovation: Is the project original and innovative?  For example: Does the project challenge existing paradigms or clinical practice; address an innovative hypothesis or critical barrier to progress in the field?  Does the project develop or employ novel concepts, approaches, methodologies, tools, or technologies for this area?  

Specific to this FOA:

Investigators: Are the PD/PI(s) and other key personnel appropriately trained and well suited to carry out this work?  Is the work proposed appropriate to the experience level of the principal investigator(s) and other researchers?  Does the PD/PI(s) and investigative team bring complementary and integrated expertise to the project (if applicable)?

Specific to this FOA:

Environment:  Do(es) the scientific environment in which the work will be done contribute to the probability of success? Do the proposed studies benefit from unique features of the scientific environment, or subject populations, or employ useful collaborative arrangements? Is there evidence of institutional support?

Specific to this FOA:

Is there evidence in the application for multi-disciplinary interactions and effective communication, interaction, and integration across disciplines involved in the project? Have the investigators provided adequate evidence that they have access to the technologies, methodologies, and specimen resources that are required?  

2.A. Additional Review Criteria

In addition to the above criteria, the following items will continue to be considered in the determination of scientific merit and the priority score:

Protection of Human Subjects from Research Risk: The involvement of human subjects and protections from research risk relating to their participation in the proposed research will be assessed.  See the “Human Subjects Sections” of the PHS398 Research Plan component of the SF424 (R&R).

Inclusion of Women, Minorities and Children in Research: The adequacy of plans to include subjects from both genders, all racial and ethnic groups (and subgroups), and children as appropriate for the scientific goals of the research will be assessed.  Plans for the recruitment and retention of subjects will also be evaluated.  See the “Human Subjects Sections” of the PHS398 Research Plan component of the SF424 (R&R)
 
Care and Use of Vertebrate Animals in Research: If vertebrate animals are to be used in the project, the adequacy of the plans for their care and use will be assessed.  See the “Other Research Plan Sections” of the PHS398 Research Plan component of the SF424 (R&R). 

Biohazards: If materials or procedures are proposed that are potentially hazardous to research personnel and/or the environment, determine if the proposed protection is adequate.

2.B. Additional Review Considerations

Budget and Period of Support: The reasonableness of the proposed budget and the appropriateness of the requested period of support in relation to the proposed research may be assessed by the reviewers.  The priority score should not be affected by the evaluation of the budget.

2. C. Sharing Research Data

Data Sharing Plan: The reasonableness of the data sharing plan will be assessed by the reviewers.  Reviewers will factor the proposed data sharing plan into the determination of scientific merit or the priority score.  The presence of a data sharing plan will be part of the terms and conditions of the award.  The funding organization will be responsible for monitoring the data sharing policy.  The plans for data sharing must include the statement that applicants will deposit data in an appropriate database compatible with those that are developed and maintained by the NCI Center for Bioinformatics (CB), if suitable.  Reviewers will be asked to assess how well the applicants describe their use of NCI CB-supported resources where that is possible and how appropriate are their plans to ensure that the NCI CB will be able to access any other data stores which they plan to use.  For more information on data sharing, see: http://grants.nih.gov/grants/policy/data_sharing; and http://grants.nih.gov/grants/policy/data_sharing_faqs.htm. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score.

2.D. Sharing Research Resources

NIH policy expects that grant recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (see the NIH Grants Policy Statement at http://grants.nih.gov/archive/grants/policy/nihgps_2003/index.htm#_Toc54600131). Investigators responding to this funding opportunity should include a sharing research resources plan addressing how unique research resources will be shared or explain why sharing is not possible.

Program staff will be responsible for the administrative review of the plan for sharing research resources.

The adequacy of the resources sharing plan and any related data sharing plans will be considered by Program staff of the funding organization when making recommendations about funding applications.  The effectiveness of the resource sharing will be evaluated as part of the administrative review of each Non-Competing Grant Progress Report (PHS 2590), see Section VI.3., “Reporting.”

Model Organism Sharing Plan: Reviewers are asked to assess the sharing plan in an administrative note.  The sharing plan itself should be discussed after the application is scored.  Whether a sharing plan is reasonable can be determined by the reviewers on a case-by-case basis, taking into consideration the organism, the timeline, the applicant's decision to distribute the resource or deposit it in a repository, and other relevant considerations.

3. Anticipated Announcement and Award Dates

Not Applicable

Section VI. Award Administration Information


1. Award Notices

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the NIH eRA Commons

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant.  For details, applicants may refer to the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization.  The NoA signed by the grants management officer is the authorizing document.  Once all administrative and programmatic issues have been resolved, the NoA will be generated via email notification from the awarding component to the grantee business official.

Selection of an application for award is not an authorization to begin performance.  Any costs incurred before receipt of the NoA are at the recipient's risk.  These costs may be reimbursed only to the extent considered allowable pre-award costs.  See Section IV.5., “Funding Restrictions.”

2. Administrative and National Policy Requirements

Awardees will be expected to make all of the data (i.e. information resources, reagents, and technologies) produced under these awards publicly available.  The plans for data sharing must include the statement that applicants will deposit data in an appropriate database maintained by the NCI Center for Bioinformatics, if a suitable database exists.

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA.  For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General  and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities.

3. Reporting

When multiple years are involved, awardees will be required to submit the Non-Competing Grant Progress Report (PHS 2590) annually and financial statements as required in the NIH Grants Policy Statement.

Section VII. Agency Contacts


We encourage your inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.  Inquiries may fall into three areas: scientific/research, peer review, and financial or grants management issues:

1. Scientific/Research Contact(s):

Anne S. Tatem
Division of Cancer Biology
National Cancer Institute
6130 Executive Boulevard, Suite 5056, MSC 7380
Bethesda, MD 20892-7380
Telephone: (301) 594-5371
Fax: (301) 496-8656
Email: tatema@mail.nih.gov

2. Peer Review Contact(s):

Referral Officer
National Cancer Institute
Division of Extramural Activities
6116 Executive Boulevard, Room 8041, MSC 8329
Bethesda, MD 20892-8329 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express mail/courier delivery)
Telephone: (301) 496-3428
Fax: (301) 402-0275
Email: ncidearefof@mail.nih.gov

3. Financial/Grants Management Contact(s):

Lan Hoang
Office of Grants Administration
National Cancer Institute
6120 Executive Boulevard, EPS Room 243, MSC 7150
Bethesda, MD 20892-7150 (for U.S. Postal Service express or regular mail)
Rockville, MD 20852 (for express/courier delivery)
Telephone: (301) 496-9048
Fax: (301) 496-8601
Email:  hoangla@mail.nih.gov

Section VIII. Other Information


Required Federal Citations

Use of Animals in Research:
Recipients of PHS support for activities involving live, vertebrate animals must comply with PHS Policy on Humane Care and Use of Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf) as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm), and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm) as applicable.

Human Subjects Protection:
Federal regulations (45 CFR 46) require that applications and proposals involving human subjects must be evaluated with reference to the risks to the subjects, the adequacy of protection against these risks, the potential benefits of the research to the subjects and others, and the importance of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).

Data and Safety Monitoring Plan:
Data and safety monitoring is required for all types of clinical trials, including physiologic toxicity and dose-finding studies (Phase I); efficacy studies (Phase II); and efficacy, effectiveness, and comparative trials (Phase III).  Monitoring should be commensurate with risk.  The establishment of data and safety monitoring boards (DSMBs) is required for multi-site clinical trials involving interventions that entail potential risks to the participants (“NIH Policy for Data and Safety Monitoring,” NIH Guide for Grants and Contracts, http://grants.nih.gov/grants/guide/notice-files/not98-084.html).

Sharing Research Data:
Investigators submitting an NIH application seeking $500,000 or more in direct costs in any single year are expected to include a plan for data sharing or state why this is not possible (http://grants.nih.gov/grants/policy/data_sharing).

Investigators should seek guidance from their institutions, on issues related to institutional policies and local institutional review board (IRB) rules, as well as local, State, and Federal laws and regulations, including the Privacy Rule.  Reviewers will consider the data sharing plan but will not factor the plan into the determination of the scientific merit or the priority score.

Access to Research Data through the Freedom of Information Act:
The Office of Management and Budget (OMB) Circular A-110 has been revised to provide access to research data through the Freedom of Information Act (FOIA) under some circumstances.  Data that are: (1) first produced in a project that is supported in whole or in part with Federal funds; and (2) cited publicly and officially by a Federal agency in support of an action that has the force and effect of law (i.e., a regulation) may be accessed through FOIA.  It is important for applicants to understand the basic scope of this amendment. NIH has provided guidance at http://grants.nih.gov/grants/policy/a110/a110_guidance_dec1999.htm.  Applicants may wish to place data collected under this funding opportunity in a public archive, which can provide protections for the data and manage the distribution for an indefinite period of time.  If so, the application should include a description of the archiving plan in the study design and include information about this in the budget justification section of the application.  In addition, applicants should think about how to structure informed consent statements and other human subjects procedures given the potential for wider use of data collected under this award.

Sharing of Model Organisms:
NIH is committed to support efforts that encourage sharing of important research resources including the sharing of model organisms for biomedical research (see http://grants.nih.gov/grants/policy/model_organism/index.htm).  At the same time, the NIH recognizes the rights of grantees and contractors to elect and retain title to subject inventions developed with Federal funding pursuant to the Bayh-Dole Act (see the NIH Grants Policy Statement).  Beginning October 1, 2004, all investigators submitting an NIH application or contract proposal are expected to include in the application/proposal a description of a specific plan for sharing and distributing unique model organism research resources generated using NIH funding or state why such sharing is restricted or not possible.  This will permit other researchers to benefit from the resources developed with public funding.  The inclusion of a model organism sharing plan is not subject to a cost threshold in any year and is expected to be included in all applications where the development of model organisms is anticipated.

Inclusion of Women And Minorities in Clinical Research:
It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH-supported clinical research projects unless a clear and compelling justification is provided indicating that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research.  This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43).  All investigators proposing clinical research should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research” (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-001.html); a complete copy of the updated Guidelines is available at http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. The amended policy incorporates: the use of an NIH definition of clinical research; updated racial and ethnic categories in compliance with the new OMB standards; clarification of language governing NIH-defined Phase III clinical trials consistent with the SF424 (R&R) application; and updated roles and responsibilities of NIH staff and the extramural community.  The policy continues to require for all NIH-defined Phase III clinical trials that: a) all applications or proposals and/or protocols must provide a description of plans to conduct analyses, as appropriate, to address differences by sex/gender and/or racial/ethnic groups, including subgroups if applicable; and b) investigators must report annual accrual and progress in conducting analyses, as appropriate, by sex/gender and/or racial/ethnic group differences.

Inclusion of Children as Participants in Clinical Research:
The NIH maintains a policy that children (i.e., individuals under the age of 21) must be included in all clinical research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them.

All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines" on the inclusion of children as participants in research involving human subjects (http://grants.nih.gov/grants/funding/children/children.htm).

Required Education on the Protection of Human Subject Participants:
NIH policy requires education on the protection of human subject participants for all investigators submitting NIH applications for research involving human subjects and individuals designated as key personnel.  The policy is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

Human Embryonic Stem Cells (hESC):
Criteria for federal funding of research on hESCs can be found at http://stemcells.nih.gov/index.asp and at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html.  Only research using hESC lines that are registered in the NIH Human Embryonic Stem Cell Registry will be eligible for Federal funding (http://escr.nih.gov/).  It is the responsibility of the applicant to provide in the project description and elsewhere in the application as appropriate, the official NIH identifier(s) for the hESC line(s) to be used in the proposed research.  Applications that do not provide this information will be returned without review.

NIH Public Access Policy:
NIH-funded investigators are requested to submit to the NIH manuscript submission (NIHMS) system (http://www.nihms.nih.gov/) at PubMed Central (PMC) an electronic version of the author's final manuscript upon acceptance for publication, resulting from research supported in whole or in part with direct costs from NIH.  The author's final manuscript is defined as the final version accepted for journal publication, and includes all modifications from the publishing peer review process.

NIH is requesting that authors submit manuscripts resulting from: 1) currently funded NIH research projects; or 2) previously supported NIH research projects if they are accepted for publication on or after May 2, 2005.  The NIH Public Access Policy applies to all research grant and career development award mechanisms, cooperative agreements, contracts, Institutional and Individual Ruth L. Kirschstein National Research Service Awards, as well as NIH intramural research studies.  The Policy applies to peer-reviewed, original research publications that have been supported in whole or in part with direct costs from NIH, but it does not apply to book chapters, editorials, reviews, or conference proceedings.  Publications resulting from non-NIH-supported research projects should not be submitted.

For more information about the Policy or the submission process, please visit the NIH Public Access Policy Web site at http://publicaccess.nih.gov// and view the Policy or other Resources and Tools, including the Authors' Manual.

Standards for Privacy of Individually Identifiable Health Information:
The Department of Health and Human Services (HHS) issued final modification to the "Standards for Privacy of Individually Identifiable Health Information", the "Privacy Rule", on August 14, 2002. The Privacy Rule is a federal regulation under the Health Insurance Portability and Accountability Act (HIPAA) of 1996 that governs the protection of individually identifiable health information, and is administered and enforced by the HHS Office for Civil Rights (OCR).

Decisions about applicability and implementation of the Privacy Rule reside with the researcher and his/her institution.  The OCR website (http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including a complete Regulation Text and a set of decision tools on "Am I a covered entity?"  Information on the impact of the HIPAA Privacy Rule on NIH processes involving the review, funding, and progress monitoring of grants, cooperative agreements, and research contracts can be found at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-03-025.html.

URLs in NIH Grant Applications or Appendices:
All applications and proposals for NIH funding must be self-contained within specified page limitations.  For publications listed in the appendix and/or Progress report, Internet addresses (URLs) or PubMed Central (PMC) submission identification numbers must be used for publicly accessible on-line journal articles.  Publicly accessible on-line journal articles or PMC articles/manuscripts accepted for publication that are directly relevant to the project may be included only as URLs or PMC submission identification numbers accompanying the full reference in either the Bibliography & References Cited section, the Progress Report Publication List section, or the Biographical Sketch section of the NIH grant application.  A URL or PMC submission identification number citation may be repeated in each of these sections as appropriate.  There is no limit to the number of URLs or PMC submission identification numbers that can be cited.

Healthy People 2010:
The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010," a PHS-led national activity for setting priority areas.  This FOA is related to one or more of the priority areas.  Potential applicants may obtain a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.

Authority and Regulations:
This program is described in the Catalog of Federal Domestic Assistance at http://www.cfda.gov/ and is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.  Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Parts 74 and 92.  All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

The PHS strongly encourages all grant recipients to provide a smoke-free workplace and discourage the use of all tobacco products.  In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care, or early childhood development services are provided to children.  This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.

Loan Repayment Programs:
NIH encourages applications for educational loan repayment from qualified health professionals who have made a commitment to pursue a research career involving clinical, pediatric, contraception, infertility, and health disparities related areas.  The LRP is an important component of NIH's efforts to recruit and retain the next generation of researchers by providing the means for developing a research career unfettered by the burden of student loan debt.  Note that an NIH grant is not required for eligibility and concurrent career award and LRP applications are encouraged.  The periods of career award and LRP award may overlap providing the LRP recipient with the required commitment of time and effort, as LRP awardees must commit at least 50% of their time (at least 20 hours per week based on a 40 hour week) for 2 years to the research.  For further information, please see http://www.lrp.nih.gov/.


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.